Novo Nordisk CEO on Catalent, Ozempic and Wegovy

Описание к видео Novo Nordisk CEO on Catalent, Ozempic and Wegovy

Novo Nordisk A/S CEO Lars Fruergaard Jorgensen discusses the company's acquisition of Catalent for for $16.5 billion and the production of its weight-loss drug Wegovy and diabetes treatment Ozempic.

For more on this story, please see: https://www.bloomberg.com/news/articl...
--------
Follow Bloomberg for business news & analysis, up-to-the-minute market data, features, profiles and more: http://www.bloomberg.com
Connect with us on...
Twitter:   / business  
Facebook:   / bloombergbusiness  
Instagram:   / bloombergbusiness  

Комментарии

Информация по комментариям в разработке

Похожие видео